주식/증권
➡️ 중립
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
요약
Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.